This is a Israel news story, published by Yahoo, that relates primarily to Thermo Fisher news.
For more Israel news, you can click here:
more Israel newsFor more Thermo Fisher news, you can click here:
more Thermo Fisher newsFor more disease research news, you can click here:
more disease research newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like disease research news, you might also like this article about
pharma companies. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Pfizer news, new drug development pathways news, disease research news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
CytoReasonReuters
•78% Informative
Israel 's CytoReason uses AI to develop disease models.
Nvidia , Pfizer , Thermo Fisher and venture capital investor OurCrowd participated in the round.
Pfizer expanded its partnership with Cytoreason with a $20 million investment that could reach $110 million by 2027 .
VR Score
89
Informative language
98
Neutral language
9
Article tone
formal
Language
English
Language complexity
77
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links